Peer-reviewed journal articles (187)
  1. 73. Huysseune, S., Kienlen-Campard, P. K., Hébert, S., Tasiaux, B., Leroy, K., Devuyst, O., Brion, J. P., De Strooper, B., & Octave, J. N. (2009). Epigenetic control of aquaporin 1 expression by the amyloid precursor protein. The FASEB journal, 23(12), 4158-4167. doi:10.1096/fj.09-140012
  2. 74. Vuckovic, A., Rondelet, B., Brion, J. P., & Naeije, R. (2009). Expression of vasoactive intestinal peptide and related receptors in overcirculation-induced pulmonary hypertension in piglets. Pediatric research, 66(4), 395-399. doi:10.1203/PDR.0b013e3181b33804
  3. 75. Leroy, K., De Decker, R., Suain, V., Authelet, M., Yilmaz, Z., & Brion, J. P. (2009). C9 Tau et toxicité de l’amyloïde Aß dans les modèles transgéniques APP. Revue neurologique, 165(10), 23. doi:10.1016/S0035-3787(09)72562-7
  4. 76. Gankam Kengne, F., Soupart, A., Pochet, R., Brion, J. P., & Decaux, G. (2009). Re-induction of hyponatremia after rapid overcorrection of hyponatremia reduces mortality in rats. Kidney international, 76(6), 614-621. doi:10.1038/ki.2009.254
  5. 77. Killick, R., Scales, G., Leroy, K., Causevic, M., Hooper, C., Irvine, E. E., Choudhury, A. I., Drinkwater, L., Kerr, F., Al-Qassab, H., Stephenson, J., Yilmaz, Z., Giese, K. P., Brion, J. P., Withers, D. J., & Lovestone, S. (2009). Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice. Biochemical and biophysical research communications, 386(1), 257-262. doi:10.1016/j.bbrc.2009.06.032
  6. 78. Boom, A., Authelet, M., Dedecker, R., Frédérick, C., Van Heurck, R., Daubie, V., Leroy, K., Pochet, R., & Brion, J. P. (2009). Bimodal modulation of tau protein phosphorylation and conformation by extracellular Zn2+ in human-tau transfected cells. Biochimica et biophysica acta, 1793(6), 1058-1067. doi:10.1016/j.bbamcr.2008.11.011
  7. 79. Langer, I., Leroy, K., Gaspard, N., Brion, J. P., & Robberecht, P. (2008). Cell surface targeting of VPAC1 receptors: evidence for implication of a quality control system and the proteasome. Biochimica et biophysica acta, 1783(9), 1663-1672. doi:10.1016/j.bbamcr.2008.03.013
  8. 80. Brion, J. P. (2008). Biological models in frontotemporal dementias. Handbook of clinical neurology, 89, 449-455. doi:10.1016/S0072-9752(07)01241-9
  9. 81. Leroy, K., Bretteville, A., Schindowski, K., Gilissen, E., Authelet, M., De Decker, R., Yilmaz, Z., Buée, L., & Brion, J. P. (2007). Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice. The American journal of pathology, 171(3), 976-992. doi:10.2353/ajpath.2007.070345
  10. 82. Leroy, K., Yilmaz, Z., & Brion, J. P. (2007). Increased level of active GSK-3β in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathology and applied neurobiology, 33(1), 43-55. doi:10.1111/j.1365-2990.2006.00795.x
  11. 83. Pierrot, N., Santos, S. F., Feyt, C., Morel, M., Brion, J. P., & Octave, J. N. (2006). Calcium-mediated transient phosphorylation of tau and amyloid precursor protein followed by intraneuronal amyloid-beta accumulation. The Journal of biological chemistry, 281(52), 39907-39914. doi:10.1074/jbc.M606015200
  12. 84. Schindowski, K., Bretteville, A., Leroy, K., Bégard, S., Brion, J. P., Hamdane, M., & Buée, L. (2006). Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. The American journal of pathology, 169(2), 599-616. doi:10.2353/ajpath.2006.060002
    13. << Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 Next >>